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Predictors of Acute Liver Failure in Patients With Acute 
Hepatitis A: An Analysis of the 2016–2018 San Diego 
County Hepatitis A Outbreak
Aiyang A. Jiang,1 Holly S. Greenwald,1 Lamiya Sheikh,2 Darcy A. Wooten,3 Atul Malhotra,4 Robert T. Schooley,3 and Daniel A. Sweeney4
1Department of Medicine, University of California, San Diego, La Jolla, California, USA, 2Washington Hospital, Fremont, California, USA, 3Division of Infectious Diseases, Department of Medicine, 
University of California, San Diego, La Jolla, California, USA, and 4Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California, San Diego, La Jolla, 
California, USA
Background. Between 2016 and 2018, San Diego County experienced a hepatitis A outbreak with a historically high mortality 
rate (3.4%) that highlighted the need for early recognition of those at risk of developing acute liver failure (ALF).
Methods. A retrospective case series of adult hospitalized patients with acute hepatitis A.
Results. One hundred six patients with hepatitis A were studied, of whom 11 (10.4%) developed ALF, of whom 7 (6.6%) died. 
A history of alcohol abuse, hyperbilirubinemia, hypoalbuminemia, hyponatremia, and anemia were associated with increased odds 
of developing ALF. Initial Maddrey’s and Model of End-Stage Liver Disease Sodium (MELD-Na) scores were also associated with 
the development of ALF. Multivariable analysis showed that a higher initial MELD-Na score (odds ratio [OR], 1.205; 95% confidence 
interval [CI], 1.018–1.427) and a lower initial serum albumin concentration (OR, 9.35; 95% CI, 1.15–76.9) were associated with in-
creased odds of developing ALF. Combining serum albumin and MELD-Na (SAM; C-statistic, 0.8878; 95% CI, 0.756–0.988) yielded 
a model that was not better than either serum albumin (C-statistic, 0.852; 95% CI, 0.675–0.976) or MELD-Na (C-statistic, 0.891; 
95% CI, 0.784–0.968; P = .841). Finally, positive blood cultures were more common among patients with ALF compared with those 
without ALF (63.6% vs 4.3%; P < .00001).
Conclusions. Hypoalbuminemia was associated with an increased risk of ALF in patients with acute hepatitis A. Positive blood 
cultures and septic shock as a cause of death were common among patients with ALF. Providers caring for patients with acute hepatitis 
A should monitor for early signs of sepsis and consider empiric antibiotics, especially in patients presenting with hypoalbuminemia.
Keywords. acute liver failure; hepatitis A; MELD-Na score; serum albumin.
Until recently, hepatitis A infection in the United States was rel-
atively uncommon, with 2007 recorded cases in 2016, most of 
which were related to contaminated food sources [1]. Between 
2016 and 2018, San Diego County endured one of the largest 
person-to-person hepatitis A  outbreaks in the United States 
since the hepatitis A  vaccine was introduced in 1996, with a 
total of 591 cases and 20 deaths [1–3]. Hepatitis A–associated 
mortality is largely a function of acute liver failure (ALF) and its 
associated complications of coagulopathy, encephalopathy, and 
secondary infection. In case series, 31% to 60% of patients with 
ALF secondary to hepatitis A  either died or underwent liver 
transplant [3–5]. Early identification of risk factors for ALF is 
desirable, as this information would aid in the timely triage of 
these patients to higher-level care and possibly guide empiric 
therapies. To date, there are only a few reports that describe risk 
factors for the development of ALF in the setting of acute hep-
atitis A, and none of these studies involve patients from any of 
the recent US hepatitis A outbreaks [6–8]. The aim of this study 
was to identify patient characteristics—available at the time of 
initial presentation to a health care provider—that could be 
useful in predicting whether a patient with hepatitis A was at 
increased risk of developing ALF.
METHODS
Data Collection
We performed a retrospective cohort study using patient data 
collected from the electronic medical records of all patients 
hospitalized at the University of California San Diego Hillcrest 
Hospital from November 1, 2016, to October 10, 2017. Patients 
were included if they had a positive hepatitis A IgM antibody 
identified during this time period. Patients were excluded if they 
were younger than 18 years of age, incarcerated, or pregnant.
Patient data that were available at the time of presentation 
were collected, including age, gender, domicile status, history 
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of substance use (methamphetamine, opioids, and cocaine via 
chart review and urine toxicology reports), HIV status, hepa-
titis B surface antigen positivity, hepatitis C viral load, history 
of cirrhosis or other previous abnormal liver imaging, initial 
vital signs, initial complete blood counts, initial complete met-
abolic panels, and initial coagulation profile. Alcohol abuse 
was determined based on chart review searching for provider 
documentation of alcohol abuse disorder. MELD-Na score 
[MELD Score - Na - 0.025  * MELD * (140 - Na) +  140] and 
Maddrey’s Discriminant Function (4.6*(PT – Control PT) + 
Total Bilirubin) were calculated using laboratory results on 
presentation to the emergency department [9, 10]. At presen-
tation or at any time during hospitalization, ALF was defined 
as an International Normalized Ratio (INR) >1.5, hepatic en-
cephalopathy, and acute liver injury developing within 26 
weeks of hepatitis A  infection in an individual without any 
known previous liver disease. Subsequent inpatient data were 
also collected, including presence of blood culture results, need 
for intensive care therapies, N-acetylcysteine (NAC) treatment, 
and—when a patient had expired—a cause of death.
Statistical Analysis
Bivariable comparisons between patients with and without 
ALF were made using the Fisher exact test and the chi-square 
test for categorical variables and the Mann-Whitney and inde-
pendent t tests for continuous variables in order to determine 
independent predictors of ALF. Multivariable logistic regres-
sion analysis was used to analyze variables that were found to 
be significantly associated with ALF. The parameters of the 
final model were used to weigh the contribution of each var-
iable in determining prognostic accuracy. Receiver operating 
characteristic (ROC) curves and area under the ROC curves 
were used to assess the accuracy of MELD-Na and SAM, a 
measure that incorporated both the patient’s serum albumin 
concentration and MELD-Na score. ROC analysis with leave-
1-out cross-validation was applied to evaluate model perfor-
mance. DeLong’s test was used to compare ROC curves. P 
values for C-statistics were calculated with the use of the boot-
strap method (10 000 times bootstrap resampling). Statistical 
significance was considered within a 95% confidence interval. 
All statistical analyses were performed with R statistical soft-
ware, version 3.5.1 (http://www.r-project.org).
RESULTS
Presenting Characteristics of Acute Hepatitis A  Patients With and 
Without ALF
During the study period, 106 individuals were hospitalized with 
acute hepatitis A, including 11 patients who developed ALF, of 
whom 7 died. Table 1 shows the baseline characteristics and 
clinical data available at the time of presentation to the emer-
gency department of all patients admitted with acute hepatitis 
A and compares the subsets of patients with and without ALF. 
The mean patient age was 46 ± 11.9  years, with the majority 
being homeless men with a history of substance use. Bivariable 
analysis revealed that patients with hepatitis A  infection who 
progressed to ALF compared with patients who did not develop 
ALF were more likely to have a history of alcohol use disorder 
(90.9% vs 39.1%; P = .002), a lower serum albumin (2.3 vs 3.1; 
P = .0006), a lower hemoglobin (11.7 vs 13.3; P = .04), a lower 
serum sodium (127.5 vs 134.6; P = .0002), a higher Maddrey’s 
Discriminant Function (63.9 vs 21.1; P  =  .03), and a higher 
MELD-Na score (29.5 vs 19.6; P < .0001). Alternatively, patient 
age, history of hepatitis C co-infection (18.2% vs 5.6%; P = .28), 
initial vital signs, initial white blood cell count (10.5 vs 7.8; 
P = .26), and initial creatinine (1.4 vs 0.8; P = .15) were not sig-
nificantly associated with the development of ALF among pa-
tients presenting with acute hepatitis A. Prior serum albumin 
levels (within the previous 17 months) were documented in 7 
of 11 cases (data not shown). Only 1 patient had a prior normal 
serum albumin concentration (3.6  g/dL, normal defined as 
3.4–5.4 g/dL).
Multivariable Analysis of Presenting Characteristics of Patients Who 
Developed Acute Liver Failure
Multivariate analysis identified every 1-g/dL decrease of initial 
serum albumin from 4 g/dL (odds ratio [OR], 9.35; 95% confi-
dence interval [CI], 1.15–76.9) and a higher MELD-Na score 
(OR, 1.205; 95% CI, 1.018–1.427) as the only 2 variables avail-
able at the time of presentation that independently predicted 
ALF in patients with acute hepatitis A (Table 2).
Serum Albumin, MELD-Na, and SAM as Predictors of ALF Due to Hepatitis A
ROC curves predicting ALF were constructed for serum al-
bumin, MELD-Na, and SAM (Figure 1). Of the patients who 
developed ALF, 82% (9 of 11) had an albumin <2.45, whereas 
in the non-ALF group, only 9.5% (9 of 95)  had an albumin 
level <2.45. SAM was calculated using the following equation: 
SAM = MELD-Na + 11.99 * (4—Initial Albumin). The associ-
ated sensitivity, specificity, best cutoff value, and Youden Index 
for each curve are shown in Table 3. As INR is a component of 
the possible predictors MELD-Na and SAM and also a com-
ponent of the outcome of interest, ALF, ROC analysis was also 
performed using SAM and MELD-Na without INR (data not 
shown), which resulted in a similar C-statistic (0.8745 for SAM 
without INR vs 0.8878 for SAM; P  =  .841). Serum albumin, 
MELD-Na SAM, and MELD-Na ROC curves did not differ sta-
tistically in terms of predicting ALF (P = .841).
As all 3 measures were not dissimilar in terms of predicting 
ALF, further analysis focused on serum albumin, the easiest of 
the 3 variables to measure. Internal validation analysis was per-
formed using both bootstrap analysis (C-statistic, 0.8000) and 
leave-1-out cross-validation to evaluate model performance 
and showed a prediction error for serum albumin of 0.06416 
(bias-corrected cross-validation error, 0.06413).
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Hospital Course and Outcomes of Hepatitis A Patients With ALF
All patients with hepatitis A and ALF were evaluated for liver 
transplant, although none were deemed candidates due to home-
lessness, comorbid conditions, or active substance abuse. Five 
of 11 ALF patients were admitted directly to the ICU (Table 4), 
whereas 5 other patients did not have ALF on presentation 
but were diagnosed during their hospital stay and needed ICU 
transfer. Seven of 11 patients with ALF had positive blood cul-
tures (including 4 patients with positive blood cultures within 
24 hours of admission), compared with 2 of 47 (only 47 out of 
Table 1. Bivariable Comparison of Clinical Parameters and Patient Characteristics Between Hepatitis A Patients With and Without Acute Liver Failure
 All Patients (n = 106) No-ALF (n = 95, 89.6%) ALF (n = 11, 10.4%) P
Demographics
Age, y 46 ± 11.9 45.3 ± 11.8 52.1 ±11.8 .09
Female 31 (29.2) 28 (29.5) 3 (27.3) 1
Ethnicity    .3
 Caucasian 72 (67.9) 62 (65.3) 10 (90.9)  
 African American 17 (16) 17 (17.9) 0 (0)  
 Hispanic 17 (16) 16 (16.8) 1 (9.1)  
Homeless 73 (68.9) 63 (66.3) 10 (90.9) .17
Comorbidities
History of cirrhosis 3 (2.8) 3 (3.2) 0 (0) .55
Alcohol use disorder history 46 (44.7) 36 (39.1) 10 (90.9) .002
Hepatitis B positive 3 (2.8) 3 (3.2) 0 (0) .55
Hepatitis C positive 7 (6.9) 5 (5.6) 2 (18.2) .28
Initial vital signs
Heart rate, BPM 93.1 ± 16.5 92.9 ± 14.6 93.8 ± 29.7 .93
Systolic BP, mmHg 121.5 ± 19.8 122.7 ± 19.7 111.1 ± 18.1 .07
Diastolic BP, mmHg 75 ± 13.4 75.8 ± 13.4 68.5 ± 12.2 .09
Mean arterial pressure, mmhg 90.5 ± 14.3 91.41 ± 14.2 82.7 ± 12.8 .06
Temperature, ºF 98.6 ± 1.3 98.6 ± 1.2 98.6 ± 1.9 .93
Respiratory rate, RPM 17.5 ± 2.1 17.5 ± 1.9 18 ± 2.7 .54
SaO2, % 97.9 ± 0 1.7 97.9 ± 1.6 97.5 ± 2.5 .63
Initial labs
AST, U/L 1003 (25–7000) 994 (25–7000) 2573 (137–7000) .08
ALT, U/L 1371 (13–7000) 1461 (13–6681) 991 (91–7000) .37
Albumin, g/dL 3.0 ± 0.5 3.1 ± 0.5 2.3 ± 0.5 .0006
Bilirubin, mg/dL 6.5 (0.2–44.6) 6.1 (0.2–44.6) 14.4 (0.6–27.8) .04
Alkaline phosphatase, U/L 206.5 (59–868) 209 (59–868) 201 (83–666) .97
WBC, 1000/mm3 8 ± 12.8 7.8 ± 13.3 10.5 ± 6.2 .26
Hb, gm/dL 13. 1 ± 2.2 13.3 ± 2.1 11.7 ± 2.1 .04
Creatinine, mg/dL 0.9 ± 0.5 0.8 ± 0.3 1.4 ± 1.2 .15
Platelet, 1000/mm3 234.2 ± 80.4 235 ± 77.8 227.3 ± 104.2 .82
BUN, mg/dL 13.6 ± 9.5 12.5 ± 6.9 23 ± 12.3 .1
Na, mmol/L 133.8 ± 4.8 134.6 ± 0 4.3 127.5 ± 4.4 .0002
Phosphate, mg/dL 2.9 ± 1.2 2.9 ± 0.7 3.1 ± 2.9 .84
Lactate, mmol/L 2.9 ± 3.8 2.1 ± 1.3 5.9 ± 7.4 .14
Bicarb, mmol/L 24.1 ± 3.9 24.3 ± 3.1 22.4 ± 8.5 .47
Initial prognostic scores
Maddrey’s Discriminant Score 25.7 ± 31 21.1 ± 22.7 63.9 ± 57.7 .03
MELD-Na 20.7 ± 6 19.6 ± 5.0 29.5 ± 6.9 <.0001
All variables are presented as No. (%), mean ± SD, or median (range).
Abbreviations: ALF, acute liver failure; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferace; BP, blood pressure; BPM, beats per minute; BUN, Blood Urea Nitrogen; MELD-NA, 
Model of End-Stage Liver Disease Sodium; RPM, Respirations Per Minute; SAM, serum albumin and MELD-Na; WBC, white blood cell count.
Table 2. Multvariate Logistic Regression Analysis of Factors Associated With Acute Liver Failure
Factor Odds Ratio 95% CI P
Initial MELD-Na 1.205 1.018–1.427 .031
Initial serum albumin (every decrease of 1 g/dL from 4 g/dL) 9.346 1.151–76.923 .037
Abbreviations: CI, confidence interval; MELD-NA, Model of End-Stage Liver Disease Sodium.
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95 non-ALF patients received blood cultures) hepatitis A  pa-
tients without ALF (63.6% vs 4.3%; P < .00001). In the majority 
of cases, blood culture positivity occurred in 1 of 2 sets and was 
due to a variety of organisms including methicillin-resistant 
Staphylococcus aureus (n  =  1), Staphylococcus epidermidis 
(n  =  2), Staphylococcus hominis (n  =  2), and Escherichia coli 
(n = 2) (Table 4). Analysis of a potential clinical benefit of em-
piric antibiotics in the emergency department was not feasible 
because of the broad variation in antibiotic choice, dose, and 
timing of administration. The most common cause of death 
among patients who developed ALF was septic shock. Patients 
with ALF were more likely to be treated with NAC within the 
first 24 hours of presentation (45.5% vs 18.8%; P = .05); how-
ever, multivariable analysis did not detect a mortality benefit 
(data not shown). Within this case series, 18 of the 95 non-ALF 
patients and 5 of the 11 ALF patients received NAC therapy, 
with 1 ALF survivor having received NAC and 4 of the 7 de-
ceased patients having received NAC. ALF patients, compared 
with non-ALF patients, also required more intensive care ther-
apies, including mechanical ventilation (27.3% vs 3.2%), renal 
replacement therapy (36.4% vs 2.1%), and vasopressor therapy 
(45.5% vs 3.2%; P < .005 for all).
DISCUSSION
Emergency medicine providers in the United States are likely 
to face increasing numbers of patients with acute hepatitis 
A, including patients at risk for ALF. Besides California, nu-
merous other states have experienced recent outbreaks, in-
cluding Arizona, Indiana, Kentucky, Michigan, Missouri, Ohio, 
Tennessee, Utah, and West Virginia [1]. Centers for Disease 
Control and Prevention analyses of these outbreaks have iden-
tified homelessness and substance use disorder as risk factors 
associated with patients infected with hepatitis A.  However, 
the risk factors available at the time of presentation to a med-
ical provider that are associated with the development of sub-
sequent acute liver failure are not known [1]. Although most 
children aged <6 years infected with hepatitis A are asympto-
matic, the majority of adults with acute hepatitis A experience a 
severe clinical course [11]. As the hepatitis A vaccine has been 
administered to American children since 1996, adults now 
represent the population at greatest risk for hepatitis A in the 
United States.
Our analysis of a large subset of patients from the 2016–2018 
hepatitis A outbreak in San Diego (106 of the 592 total cases in-
cluding 8 of the 20 patients who died) showed that initial serum 
albumin and MELD-Na scores were independently associated 
with the development of ALF patients with hepatitis A.  The 
model combining serum albumin and MELD-Na (SAM) did 
not prove to be superior statistically to either serum albumin or 
MELD-Na. Considering the ease of measuring serum albumin 
compared with calculating MELD-Na or SAM, serum albumin 
has better clinical potential to be used as a tool for identifying 
patients with acute hepatitis A  who are at increased risk for 
developing ALF.
Serum albumin is involved in a number of physiologic func-
tions: regulation of plasma oncotic pressure (providing up to 
65%–75% of normal colloid oncotic pressure) and capillary per-
meability, compound transport, and free radical scavenging [12, 
13]. In critical illness, hypoalbuminemia is a function of loss 
due to vascular permeability, dilution with fluid resuscitation, 
and decreased albumin synthesis. Proinflammatory mediators 
such as interleukin-6 and tumor necrosis factor–α, for example, 
reduce albumin mRNA transcription. Hypoalbuminemia 
is a predictor of increased mortality across a variety patient 
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Figure 1. Receiver operating characteristic curves comparing MELD-Na, serum 
albumin, and SAM as predictors of acute liver failure. Abbreviations: MELD-NA, 
Model of End-Stage Liver Disease Sodium; SAM, serum albumin and MELD-Na.
Table 3. AUC for MELD-NA, Initial Albumin, SAM, and the Best Cutoff Values to Predict Liver Failure
Factor AUC Cutoff Value Sensitivity, % Specificity, % Youden’s Index, %
Initial MELD-Na 0.891 (0.784–0.968) 23.99 81.8 80.4 62.2
Initial albumin 0.852 (0.675–0.976) 2.45 81.8 90.2 72.0
SAM 0.888 (0.756–0.988) 46.4 81.8 88.0 69.8
Abbreviations: AUC, area under the curve; MELD-NA, Model of End-Stage Liver Disease Sodium; SAM, serum albumin and MELD-Na.
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populations and medical conditions, including sepsis, end-
stage renal disease on hemodialysis, and even femoral neck 
fracture [14].
The physiological basis for serum albumin and MELD-Na 
score being associated with ALF in hepatitis A is not obviously 
apparent. Fulminant liver injury in hepatitis A  infection is 
believed to be the result of excessive and unregulated inflam-
matory response, as the virus is not considered cytopathic to 
hepatocytes [15]. Serum albumin, a negative acute phase reac-
tant, was notably reduced in patients with ALF, a finding that is 
consistent with the theory that excessive inflammation causes 
hepatitis-related liver failure. Contrary to prior studies [11], 
we did not find that increased leukocytosis was associated with 
ALF in acute hepatitis A patients. The decreased serum albumin 
may also have been a marker of reduced synthetic function at 
baseline. Of note, bivariable analysis revealed that INR, another 
marker of synthetic function, was also elevated among ALF pa-
tients (data not shown), but because of concerns for mathemat-
ical coupling, INR was excluded from our analysis. To discern 
whether the observed hypoalbuminemia was due to preexisting 
liver disease or a function of acute hepatitis A, patient charts 
were reviewed, and prior serum albumin levels (within the 
previous 17 months) were documented in 7 of 11 cases (data 
not shown). Only 1 patient had a prior normal serum albumin 
concentration (3.6 g/dL, normal defined as 3.4–5.4 g/dL); the 
significance of this finding is limited, as these serum albumin 
measures were made in the setting of prior emergency de-
partment visits in which the patients were presumably unwell. 
Thus, it is not clear in this case series whether a relatively low 
serum albumin concentration represents baseline liver disease 
or whether it is a consequence of hepatitis A  infection. The 
MELD-Na score, on the other hand, is designed to predict the 
mortality of patients with cirrhosis and has not been previously 
applied to patients with acute liver failure to our knowledge. It 
was interesting to note that neither MELD nor serum sodium 
was individually predictive of ALF in hepatitis A.
Comparing the results of this study with prior international 
investigations of acute hepatitis revealed both similar and dis-
parate findings. In a case series of patients from Guatemala and 
Mexico, a serum albumin level of <2.5  mg/dL was associated 
with mortality, which was consistent with our ROC best cutoff 
of <2.45  mg/dL for predicting ALF [11]. On the other hand, 
our study differed from prior studies that suggested that serum 
creatinine, advanced age, alcohol use disorder, and chronic hep-
atitis B infection portended increased ALF incidence in acute 
hepatitis A [8, 11, 16]. Each of these variables was evaluated and 
was not significantly associated with ALF in our study.
The high mortality rate associated with the 2016–2018 San 
Diego hepatitis A outbreak is of particular interest. Prior hepa-
titis A outbreaks involving patients >40 years of age were char-
acterized by a mortality rate of 1.1%, whereas the San Diego 
outbreak had a mortality rate of 3.4% [17, 18]. Socioeconomic 
factors presumably contributed to this mortality rate, as most 
patients affected by the outbreak had limited access to health 
care and likely presented later in their disease course. Contrary 
to prior studies, we did not find patient age or coinfection with 
hepatitis B or C to be associated with hepatitis A–associated 
ALF, although it should be noted that this study included few 
patients with other active hepatidites (3 patients with hepatitis 
B and 7 patients with hepatitis C) [8, 16]. Also, only 1 patient 
was infected with HIV. Although the study population had a 
high prevalence of substance use disorder (59%, of whom 
55% were methamphetamine users) and homelessness (69%), 
these factors were not associated with the development of ALF. 
The viral genotype was considered a potential risk factor for 
ALF. Genotype 1B—common in the Mediterranean region 
Table 4. Patients With Acute Liver Failure and Hepatitis A: Triage, Blood Culture Data, Prior Albumin Concentration, and Cause of Death
Patient Initial Ward Bacteremia and Blood Culture Sets (+/Total) Hospital Day of Culture Positivity In-Hospital Mortality Cause of Death
1 General — — Y Hemorrhagic shock
2 ICU S. epidermidis (1/2) 1 Y Septic shock
S. hominis (1/2) 12  
E. coli (1/2) 18  
3 General — — Y Cerebral edema
4 General S. epidermidis (2/2) 0 Y Septic shock
5 ICU S. hominis (1/4) 2 Y Septic shock
6 ICU B. pumilus 
R. mucilaginosa 
S. oralis 
C. bifermentans (1/2)
0 Y Septic shock
7 General MRSA (4/4) 0 Y Septic shock
8 General E. coli (1/2) 10 N —
9 ICU — — N —
10 ICU — — N —
11 General S. hominis (1/4) 3 N —
Abbreviations: ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.
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and South Africa—historically accounts for only 2% of hepa-
titis A in the United States, yet it was exclusively identified in 
all reported cases from the San Diego outbreak [19]. Although 
some studies have suggested that there is no difference in clin-
ical presentation or severity of disease based on genotype, other 
studies have shown that genotype 1b is more often associated 
with acute liver failure [20, 21]. Given that genotype 1b is rela-
tively rare in the United States and potentially associated with 
more severe disease in outbreak settings, it is possible that this 
was a contributing factor to the high morbidity and mortality 
observed in the San Diego outbreak.
A potentially important finding of this study was the high 
rate of positive blood cultures among patients with hepatitis 
A and ALF. It is tempting to dismiss these results as contam-
inants based on the organism and the fact that many positive 
blood cultures were only 1 of 2 sets. Nonetheless, the differ-
ence in positive blood cultures between ALF and non-ALF 
patients (63.6% vs 4.3%; P  <  .00001), along with the high 
rate of septic shock as the cause of death (5/7 patients with 
ALF who died), is striking. It has been theorized that ALF in-
duces an acquired immunodeficiency due to overactivation 
of the systemic inflammatory response and Kupffer cell dys-
function [22]. Whether the higher rates of positive blood 
cultures among patients with ALF represent contaminants, 
true infection, or simply a marker of immunodeficiency is 
not clear. Unfortunately, we were not able to draw any con-
clusions regarding empiric antibiotic use in this patient co-
hort. Previous studies have looked at prophylactic antibiotics 
in all types of ALF and found no mortality benefit; the fre-
quency of positive blood cultures and septic shock as a cause 
of death among patients with hepatitis and ALF in this study 
would suggest that providers should monitor closely for 
early signs of sepsis and have a low threshold for starting 
empiric antibiotics, especially in patients with concomitant 
hypoalbuminemia [23].
Whether empiric NAC is a beneficial therapy for patients with 
acute hepatitis A could not be determined in this study. NAC 
therapy, using dosing similar to prior studies, was started within 
the first 24 hours in 86% of our patients, the majority of whom 
were given NAC for at least 24 hours [24, 25]. Multivariable 
analysis did not reveal a mortality benefit in ALF patients 
treated empirically with NAC; however, our analysis was lim-
ited by the small sample size and the fact that NAC was pre-
scribed at the discretion of the consulting hepatologist, which 
was a large confounding factor. Considering its limited side ef-
fect profile and its potential to be beneficial in ALF, early em-
piric NAC therapy before development of ALF, possibly guided 
by the patient’s serum albumin concentration, is worthy of in-
vestigation in future hepatitis A outbreaks for both preventing 
ALF and reducing mortality.
The ability to identify acute hepatitis A patients at risk for ALF 
would improve triage. Currently, such decisions are challenging. 
Many of the traditional data points used for triaging patients 
(heart or respiratory rate, Mean Arterial Pressure (MAP)) were 
not different at presentation between patients who did or did 
not develop ALF. In this study, 5 of the 11 ALF patients did not 
have ALF on presentation; however, all 5 patients eventually 
developed ALF and required transfer to the ICU. One of the 
11 patients had ALF on admission and was inappropriately tri-
aged to the step-down unit and required ICU transfer later in 
the hospital course. Although none of the patients in this study 
with ALF were deemed liver transplantation candidates due to 
poor social support and substance abuse, it would be ideal to 
be able to identify patients at risk for ALF in the event that the 
admitting hospital system is not a liver transplant center.
Several strengths of this study should be noted. The San 
Diego hepatitis A outbreak represented a unique opportunity 
to study a large sample of patients with hepatitis A, including 
patients with concomitant ALF. The high prevalence of home-
lessness and polysubstance abuse among patients and the pre-
dominant genotype, IB, are consistent with other recent and 
ongoing hepatitis A outbreaks in the United States. The finding 
of hypoalbuminemia being associated with ALF agreed with 
results from another international study, which was reassuring 
and suggested a degree of external validity. The limitations of 
this study must also be noted. Many of these patients did not 
have previous health care exposure before presentation, so it 
was difficult to rule out the presence of prior liver disease in-
cluding cirrhosis; thus, this study may have overestimated the 
incidence of ALF. The small sample size and the rarity of ALF 
are also limitations to the external validity of this study, which 
we tried to ameliorate by using internal cross-validation tech-
niques. Also, heterogenous prescribing patterns made it diffi-
cult to investigate the effect of NAC and empiric antibiotics on 
preventing ALF. Ideally, future studies would validate the pre-
dictive value of hypoalbuminemia using data obtained from 
multiple hepatitis A outbreaks.
CONCLUSIONS
Person-to-person hepatitis A  outbreaks in association with 
homeless and substance use are increasingly common events in 
the United States. There are potential advantages to the early 
identification of hepatitis A patients at increased risk for ALF. 
In this retrospective study, initial hypoalbuminemia was pre-
dictive of ALF in a large case series of patients from the 2016–
2018 San Diego hepatitis A  outbreak. Positive blood cultures 
and septic shock as a cause of death were common among 
patients with ALF. Providers caring for patients with acute 
hepatitis A  should monitor for early signs of sepsis and con-
sider empiric antibiotics, especially in patients presenting with 
hypoalbuminemia.
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